How can drug discovery for psychiatric disorders be improved?

[1]  Todd D Gould,et al.  Signal Transduction and Genes-to-Behaviors Pathways in Psychiatric Diseases , 2003, Science's STKE.

[2]  K. Kumakura,et al.  Regulation of Exocytosis through Ca2+/ATP-Dependent Binding of Autophosphorylated Ca2+/Calmodulin-Activated Protein Kinase II to Syntaxin 1A , 2002, The Journal of Neuroscience.

[3]  B. Glenthøj,et al.  Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens , 2004, Neuropsychopharmacology.

[4]  P. Greengard,et al.  Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.

[5]  G. Richter-Levin,et al.  Exposure to juvenile stress exacerbates the behavioural consequences of exposure to stress in the adult rat. , 2005, The international journal of neuropsychopharmacology.

[6]  Anthony A Grace,et al.  Gating of information flow within the limbic system and the pathophysiology of schizophrenia , 2000, Brain Research Reviews.

[7]  D. Ga.  Neurodevelopment and schizophrenia , 2002 .

[8]  Angus C Nairn,et al.  Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Karl J. Friston,et al.  Acute Remapping within the Motor System Induced by Low-Frequency Repetitive Transcranial Magnetic Stimulation , 2003, The Journal of Neuroscience.

[10]  R. Dworkin,et al.  Origins and development of schizophrenia : advances in experimental psychopathology , 1998 .

[11]  J. Callicott,et al.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.

[12]  H. Sackeim,et al.  Decreased regional brain metabolism after ect. , 2001, American Journal of Psychiatry.

[13]  T. Jay,et al.  A pathophysiological paradigm for the therapy of psychiatric disease , 2005, Nature Reviews Drug Discovery.

[14]  A. Grace.  Neurodevelopment and Schizophrenia: Developmental dysregulation of the dopamine system and the pathophysiology of schizophrenia , 2004 .

[15]  M. Raiteri,et al.  Chronic Antidepressants Reduce Depolarization-Evoked Glutamate Release and Protein Interactions Favoring Formation of SNARE Complex in Hippocampus , 2005, The Journal of Neuroscience.

[16]  J. Zohar,et al.  Setting Apart the Affected: The Use of Behavioral Criteria in Animal Models of Post Traumatic Stress Disorder , 2004, Neuropsychopharmacology.

[17]  J. Schenck.  Safety of Strong, Static Magnetic Fields , 2000, Journal of magnetic resonance imaging : JMRI.

[18]  A. Grace.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[19]  P. Somogyi,et al.  Salient features of synaptic organisation in the cerebral cortex 1 Published on the World Wide Web on 3 March 1998. 1 , 1998, Brain Research Reviews.

[20]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[21]  C D Good,et al.  The distribution of structural neuropathology in pre-clinical Huntington's disease. , 2002, Brain : a journal of neurology.

[22]  Alan C. Evans,et al.  Intellectual ability and cortical development in children and adolescents , 2006, Nature.

[23]  P. Jerabek,et al.  The functional neuroanatomy of the placebo effect. , 2002, The American journal of psychiatry.

[24]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[25]  H. Mayberg.  Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. , 2003, British medical bulletin.

[26]  Peter S Talbot,et al.  Anterior Cingulate and Subgenual Prefrontal Blood Flow Changes Following Tryptophan Depletion in Healthy Males , 2006, Neuropsychopharmacology.

[27]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[28]  B. Angrist,et al.  The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. , 1970, Biological psychiatry.

[29]  M. Egan,et al.  Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications , 2004, Biological Psychiatry.

[30]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[31]  I. Gottesman,et al.  Psychiatric endophenotypes and the development of valid animal models , 2006, Genes, brain, and behavior.

[32]  Karl J. Friston,et al.  Cerebral Blood Flow and Mental Processes in Schizophrenia , 1992, Journal of the Royal Society of Medicine.

[33]  G. Richter-Levin,et al.  Learning under stress in the adult rat is differentially affected by 'juvenile' or 'adolescent' stress. , 2006, The international journal of neuropsychopharmacology.

[34]  R. Murray,et al.  Neurodevelopment and Schizophrenia: Frontmatter , 2004 .

[35]  Bruce L McNaughton,et al.  Cannabinoids reveal importance of spike timing coordination in hippocampal function , 2006, Nature Neuroscience.

[36]  P. Whiting.  GABA-A receptors: a viable target for novel anxiolytics? , 2006, Current opinion in pharmacology.

[37]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[38]  A. Grace,et al.  Regulation of information flow in the nucleus accumbens: A model for the pathophysiology of schizophrenia. , 1998 .

[39]  Bogdan Draganski,et al.  Neuroplasticity: Changes in grey matter induced by training , 2004, Nature.

[40]  A. Prochiantz,et al.  Transduction peptides: from technology to physiology , 2004, Nature Cell Biology.

[41]  P. Somogyi,et al.  Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor γ2 F77I point mutation , 2005, The European journal of neuroscience.

[42]  F. Sulser,et al.  Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. , 1999, The international journal of neuropsychopharmacology.

[43]  Adam M. Campbell,et al.  Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression , 2004, European Neuropsychopharmacology.

[44]  G. Buzsáki.  Large-scale recording of neuronal ensembles , 2004, Nature Neuroscience.

[45]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[46]  J. Girault,et al.  Plasticity-Associated Gene Krox24/Zif268 Is Required for Long-Lasting Behavioral Effects of Cocaine , 2006, The Journal of Neuroscience.

[47]  T. Jay,et al.  Working memory deficits in adult rats after prenatal disruption of neurogenesis , 2004, Behavioural pharmacology.

[48]  P. Fitzgerald,et al.  A Randomized, Controlled Trial of Sequential Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression Method Study Design , 2022 .

[49]  H. Manji,et al.  Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention , 2004, Science's STKE.

[50]  H. Manji,et al.  The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. , 2004, The Journal of clinical psychiatry.

[51]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[52]  Schizophrenia in a molecular age , 1999 .

[53]  H. Manji,et al.  Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs , 2005, Neuropsychopharmacology.

[54]  J. Price,et al.  Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Angus C Nairn,et al.  DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.

[56]  M. Meaney,et al.  Glucocorticoid “Programming” and PTSD Risk , 2006, Annals of the New York Academy of Sciences.

[57]  Mark S. George,et al.  Prefrontal repetitive transcranial magnetic stimulation (rTMS) changes relative perfusion locally and remotely , 1999 .

[58]  A. Grace.  The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. , 1992, Journal of neural transmission. Supplementum.

[59]  Lisa M. Shin,et al.  Neurocircuitry Models of Posttraumatic Stress Disorder and Extinction: Human Neuroimaging Research—Past, Present, and Future , 2006, Biological Psychiatry.

[60]  U. Rudolph,et al.  GABA-based therapeutic approaches: GABAA receptor subtype functions. , 2006, Current opinion in pharmacology.

[61]  A. Grace,et al.  Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. , 2004, Schizophrenia bulletin.

[62]  W. Drevets,et al.  Toward Constructing an Endophenotype Strategy for Bipolar Disorders , 2006, Biological Psychiatry.

[63]  B. McEwen.  Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. , 2005, Metabolism: clinical and experimental.

[64]  P. Somogyi,et al.  Defined types of cortical interneurone structure space and spike timing in the hippocampus , 2005, The Journal of physiology.

[65]  L. Parsons,et al.  Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. , 1999, The American journal of psychiatry.

[66]  A. Rush,et al.  Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. , 2005, The Journal of clinical psychiatry.

[67]  Adam M. Campbell,et al.  Influence of predator stress on the consolidation versus retrieval of long‐term spatial memory and hippocampal spinogenesis , 2006, Hippocampus.

[68]  W. Wurst,et al.  Development of dopaminergic neurons in the mammalian brain , 2006, Cellular and Molecular Life Sciences CMLS.

[69]  Anthony A. Grace,et al.  A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia , 2006, Biological Psychiatry.

[70]  Eric J. Nestler,et al.  New approaches to antidepressant drug discovery: beyond monoamines , 2006, Nature Reviews Neuroscience.

[71]  F. Chollet,et al.  A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects , 2002, NeuroImage.

[72]  P. Greengard,et al.  Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity , 2000, The Journal of Neuroscience.

[73]  J. Csicsvari,et al.  Organization of cell assemblies in the hippocampus , 2003, Nature.

[74]  P. Greengard.  The neurobiology of slow synaptic transmission. , 2001, Science.

[75]  N. Swerdlow,et al.  Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine , 1995, Psychopharmacology.

[76]  G. Buzsáki,et al.  Neuronal Oscillations in Cortical Networks , 2004, Science.

[77]  H. Manji,et al.  Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder , 2006, Biological Psychiatry.

[78]  Jesus Bertran-Gonzalez,et al.  Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Anthony A. Grace,et al.  Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs , 1997, Trends in Neurosciences.